H., Brown-Frandsen, K., Kristensen, P., Mann, J
Recent data from the ATTAIN-MAINTAIN trial showed that patients transitioning to orforglipron after injectable GLP-1 therapy maintained their weight loss with minimal regain (approximately 0.9 kg after semaglutide transition), suggesting that oral maintenance strategies could minimize the lean mass depletion seen with prolonged high-dose injectable therapy
1d) in plasma have been correlated to cardiovascular disease
Here, we explain what antioxidants are, how they function in the body, how to increase your intake, and more
They may still see well enough to work around it
The risks around muscle loss, nutritional adequacy, and GI side effects are equally real and require active management